Your browser doesn't support javascript.
loading
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak, Daniel P; de Wit, Ronald; Chi, Kim N; Drakaki, Alexandra; Sternberg, Cora N; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed; Fléchon, Aude; Bamias, Aristotelis; Yu, Evan Y; van der Heijden, Michiel S; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Géczi, Lajos; Ou, Yen-Chuan; Coskun, Hasan Senol; Su, Wen-Pin; Hegemann, Miriam; Percent, Ivor J; Lee, Jae-Lyun; Tucci, Marcello; Semenov, Andrey; Laestadius, Fredrik; Peer, Avivit; Tortora, Giampaolo; Safina, Sufia; Del Muro, Xavier Garcia; Rodriguez-Vida, Alejo; Cicin, Irfan; Harputluoglu, Hakan; Widau, Ryan C; Liepa, Astra M; Walgren, Richard A; Hamid, Oday; Zimmermann, Annamaria H; Bell-McGuinn, Katherine M; Powles, Thomas.
Afiliação
  • Petrylak DP; Yale University School of Medicine, New Haven, CT, USA. Electronic address: daniel.petrylak@yale.edu.
  • de Wit R; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Chi KN; British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Drakaki A; David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
  • Sternberg CN; San Camillo and Forlanini Hospitals, Rome, Italy.
  • Nishiyama H; University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Castellano D; Hospital Universitario 12 de Octubre (CiberOnc), Madrid, Spain.
  • Hussain S; Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.
  • Fléchon A; Centre Léon Bérard, Lyon, France.
  • Bamias A; National and Kapodistrian University of Athens, Athens, Greece.
  • Yu EY; University of Washington, Seattle, WA, USA.
  • van der Heijden MS; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Matsubara N; National Cancer Centre Hospital East, Chiba, Japan.
  • Alekseev B; PA Herzen Moscow Oncological Research Institute, Moscow, Russia.
  • Necchi A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Géczi L; National Institute of Oncology, Budapest, Hungary.
  • Ou YC; Taichung Veterans General Hospital, Taichung, Taiwan.
  • Coskun HS; Akdeniz University School of Medicine, Antalya, Turkey.
  • Su WP; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan.
  • Hegemann M; University Hospital, Tübingen, Germany.
  • Percent IJ; Florida Cancer Specialists, Port Charlotte, FL, USA.
  • Lee JL; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea.
  • Tucci M; Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
  • Semenov A; RBHI Ivanovo Regional Oncology Dispensary, Ivanovo, Russia.
  • Laestadius F; Centre Oscar Lambret, Lille, France.
  • Peer A; Rambam Health Care Campus, Haifa, Israel.
  • Tortora G; University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Safina S; Tatarstan Regional Cancer Centre, Kazan, Russia.
  • Del Muro XG; Institut Català d'Oncologia L'Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
  • Rodriguez-Vida A; Hospital del Mar, Barcelona, Spain.
  • Cicin I; Trakya University, Edirne, Turkey.
  • Harputluoglu H; Inonu University, Malatya, Turkey.
  • Widau RC; Eli Lilly and Company, Indianapolis, IN, USA.
  • Liepa AM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Walgren RA; Eli Lilly and Company, Indianapolis, IN, USA.
  • Hamid O; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zimmermann AH; Eli Lilly and Company, Indianapolis, IN, USA.
  • Bell-McGuinn KM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK.
Lancet ; 390(10109): 2266-2277, 2017 Nov 18.
Article em En | MEDLINE | ID: mdl-28916371
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Taxoides / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Taxoides / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2017 Tipo de documento: Article